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Abstract
CD43 is a sialoglycosylated membrane protein that is involved in cell proliferation and
differentiation. CD43 glycoforms that are recognized by the UN1 monoclonal antibody (mAb)
were expressed in lymphoblastoid T-cell lines and solid tumors, such as breast, colon, gastric, and
squamous cell lung carcinomas, while unexpressed in the normal counterparts. The cancer–
association of UN1/CD43 epitope suggested the possibility to use the UN1 mAb for tumor
diagnosis and therapy.
In this study, we show that the UN1 mAb was endowed with anti-tumor activity in vivo since its
passive transfer inhibited the growth of UN1-positive HPB-ALL lymphoblastoid T-cells in mice.
Further, we demonstrate that tumor inhibition was due to UN1 mAb-dependent NK-mediated
cytotoxicity. By screening a phage displayed random peptide library we identified the phagotope
2/165 as a mimotope of the UN1 antigen, as it harboured a peptide sequence that was specifically
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recognized by the UN1 mAb and inhibited the binding of the UN1 mAb to UN1-positive tumour
cells. Based on sequence homology with the extracellular region of CD43 (amino acids 64 to 83),
the 2/165 peptide sequence was likely mimicking the protein core of the UN1/CD43 epitope.
When used as vaccine in mice, the 2/165 phagotope raised antibodies against the UN1/CD43
antigen, indicating that the 2/165 phagotope mimicked the UN1 antigen structure, and could
represent a novel immunogen for cancer immunotherapy. These findings support the feasibility to
use monoclonal antibodies to identify cancer-associated mimotopes for immunotherapy.
Keywords
Antibody immunotherapy; Immune response to cancer; Tumor antigens; CD43; UN1 monoclonal
antibody; Mimotopes; Cancer vaccine
Introduction
CD43 is a highly sialylated and O-glycosylated membrane protein with the apparent
molecular weight of 100–120 kDa, and is mostly expressed in hematopoietic cells, including
stem cells (1). CD43 is involved in multiple functions, such as cell adhesion, apoptosis and
migration (2). The UN1 monoclonal antibody (mAb) was initially selected for a high
reactivity against human immature thymocytes (CD3dim) (3), and recognized a CD43
epitope that included the monosaccharide GalNAc-O-linked to the polypeptide chain, named
UN1/CD43 antigen (4). The UN1/CD43 antigen was expressed in human thymocytes, a
subpopulation of peripheral blood CD4+ T-lymphocytes, and some leukemic T-cell lines,
such as HPB-ALL, H9, and MOLT-4 (3, 5). Moreover, the UN1/CD43 antigen was
expressed at early stages of development in foetal tissues, including thymus, spleen, adrenal
cortex, bronchial epithelium, and skin, and is down-regulated in ontogeny (6). The
involvement of UN1/CD43 glycoforms in oncogenesis was suggested by several findings. In
fact, UN1/CD43 was detected in a variety of solid tumours, including breast, colon, gastric,
and squamous cell lung carcinomas, while it was undetected in the relative normal tissues
and benign lesions (6, 7). In particular, the expression level of UN1/CD43 glycoforms in
breast cancer cells correlated with the progression stage of the disease (7). The evidence that
the UN1-type CD43 membrane proteins were expressed in cancer tissues made the UN1
mAb an attractive tool for tumor detection and immunotherapy.
Several mAbs directed against surface antigens of tumor cells are currently used for cancer
therapy (8). However, mAb-based therapy has many disadvantages, such as the relatively
short-lived response, the development of therapy-resistance and immune reaction overtime,
and a high cost-of-production (9, 10). As alternative to the direct use of therapeutic mAb,
vaccine strategies using peptide mimics of specific epitopes to elicit a humoral and cellular
immune response against tumor cells could be a more effective and economical approach
(11). In this regard, phage-displayed random peptide libraries (RPLs) have been used to
select peptides that mimic natural epitopes, so called mimotopes, even in the absence of
knowledge on the antigen structure (12). Mimotopes have been used as immunogens for
raising antibodies against the natural epitope, thus representing a suitable tool for
immunotherapy (13-16). In particular, the mimotope-based immunization can overcome the
major limitations of glycosylated antigens, including the poor immunogenicity, the inability
to stimulate a long-lasting immune response, and the difficulty to synthesize and purify large
quantities of glycosylated proteins for immunization (17). To date, a few mimotopes of
tumor antigens have been identified (18-21) some of which raised epitope-specific
antibodies for cancer vaccine (14, 22-26).
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In this study, we show that the passive transfer of the UN1 mAb inhibited the growth of
UN1-positive lymphoblastoid T-cells upon xenograft in mice, being this inhibition mediated
by antibody-dependent cell-mediated cytotoxicity. By screening a phage displayed RPL, we
identified the phagotope 2/165 that expressed the peptide sequence mimicking the UN1/
CD43 epitope, and we demonstrated that mice immunization with this phagotope elicited
antibodies that specifically recognized UN1-positive cancer tissues. These findings support
the possibility to target cancer-associated CD43 glycoforms by using immunotherapeutic
strategies based on UN1 mAb and UN1 mimotopes.
Materials and Methods
Cells
Human thymic acute lymphocytic leukaemia HPB-ALL cells were obtained by the German
Collection of Microorganisms and Cell Cultures (Braunschweig, Germany) in 2003. The cell
line was expanded and cryopreserved in liquid nitrogen in the investigators laboratory, and
lastly verified in 2013 using the following tests: morphology was evaluated by microscopic
examination, growth curve analysis was conducted, and immunophenotype of cells was
confirmed by flow cytometric analysis of cell surface markers expression. Cells were
maintained (max 25 passages) in RPMI-1640 medium supplemented with with 1% L-
glutamine and 10% Foetal Calf Serum (Life Technologies, Carlsbad, CA, USA).
Peripheral blood mononuclear cells were isolated from healthy donors by Ficoll-Paque
gradient centrifugation (GE Healthcare Life Sciences, Piscataway, NJ, USA), as previously
described (27-29). Primary cultured NK cell populations were obtained from 10-day co-
cultures of PBMCs with irradiated Epstein-Barr virus-positive RPMI 8866 lymphoblastoid
cell line, as previously described (30). HPB-ALL cells and primary cultured NK cells were
maintained in RPMI 1640 supplemented with 1% L-glutamine and 10% Foetal Calf Serum
(Life Technologies, Carlsbad, CA, USA) (31, 32).
RPL, antibodies and peptides
The f88-4/Cys5 phage displayed peptide library (GenBank Accession AF246454) was
kindly provided by Dr. George P. Smith (University of Missouri, Columbia, USA). This
library contains random 15-mer peptides constrained at the N-terminus of the pVIII phage
coat protein with a complexity of 5.9×108 primary clones (33).
The IgG1 isotype UN1 mAb was produced and purified by MAbTrap kit (GE Healthcare), as
previously described (3). Antibodies used as positive controls in ADCC were as follows:
OKT3 mAb (eBiosciences, San Diego, CA, USA), which recognizes a CD3 epitope that is
strongly expressed on HPB-ALL cells; W6/32 mAb (eBiosciences), which recognizes a non-
polymorphic epitope commonly expressed in major histocompatibility complex (MHC)
class I, HLA-A, B and C, on all human nucleated cells. FITC-conjugated F(ab')2 fragment of
rabbit anti-mouse immunoglobulins and IgG control were purchased from Dako (Milano,
Italy). Peptides were purchased from Caslo Laboratory ApS (Lyngby, Denmark).
Cell proliferation, viability, cell-cycle and apoptosis analysis
Cell proliferation was monitored by enumerating viable cells using a hemocytometer.
Viability was determined by using Trypan blue dye exclusion. Cell cycle and apoptosis
analysis were performed as previously described (34-36).
In vivo tumour growth analysis
Six weeks old female NU/NU nude mice (BALB/c congenic Crl:NU-Foxn1nu , Charles
River Laboratories, Wilmington, MA, USA) were engrafted with HPB-ALL cells (5×106)
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by subcutaneous injection into the lateral flank. Then mice were randomly assigned to two
treatment groups of 5 mice: one group was treated with control mouse IgG1 (Sigma-Aldrich,
Milano, Italy), the second group was treated with the UN1 mAb. The UN1 mAb or IgG1
control (400 μg in PBS/mouse) were injected in the tail vein of mice the day after tumor
cells engraftment and the inoculation was repeated at day 7 from xenograft. The tumour size
was measured by calliper, three times per week, and the tumour volume was calculated by
the modified ellipsoid formula π/6 × A × B2, where A is the longest and B the shortest
perpendicular axis of an assumed ellipsoid. Mice were killed when the tumor volume
reached a size of 4 cm3, according to the ethical guidelines.
Complement-dependent cytotoxicity (CDC)
For assessment of cytotoxicity, triplicate HPB-ALL samples (5×103 cells/well) were seeded
in Terasaki plates in RPMI 1640 and incubated with or without the UN1 mAb (200 μg/ml),
or W6/32 mAb (100 μg/ml), or IgG1 (100 and 200 μg/ml), in the presence or absence of the
complement for 30 min at 4°C. Then, cells were treated with rabbit complement for an
additional hour at 37°C. Cells were analysed by fluorescence microscopy to detect acridine
orange-positive viable cells (green fluorescence) and ethidium bromide-positive dead cells
(red fluorescence). Results were expressed as percentage of non-viable cells.
Antibody-dependent cellular cytotoxicity assay
NK-mediated antibody-dependent cellular cytotoxicity (ADCC) was determined using UN1-
positive HPB-ALL cells. Target cells were labelled with 51Cr (100 μCi/1×106 cells) for 1
hour at 37°C, washed twice and then incubated at room temperature for 20 minutes with the
following IgG1 isotype mAbs: UN1 mAb (0.25μg/1x106), anti-MHC class I (W6/32) (2.5μg/
1×106), and anti-CD3 (OKT3) (0.25μg/1×106). Serial dilutions of effector cells, and 51Cr-
labelled target cells (5000 /well) were plated in triplicates in round-bottomed 96-well plates
to a final volume of 200 μl RPMI supplemented with 10% FCS and 10 mM Hepes. After 4
hours incubation at 37°C, supernatant samples (30 μl) were collected from each well and
counted by a β-counter instrument (TopCount, PerkinElmer Life and Analytical Sciences,
Monza, Italy). Spontaneous release of 51Cr was evaluated by incubating the target cells with
medium alone, whereas total release was evaluated by incubating target cells with SDS 10%.
Percent specific 51Cr release was calculated according to the following formula: percent
specific release = (experimental release-spontaneous release) /(maximum release-
spontaneous release) × 100. Lytic units (LU) represent the number of effector cells required
to mediate 20% lysis of target cells and were calculated by using the descending phase of
curves generated by 51Cr release assay over the range of effector/target cell ratios, as
previously reported (37).
Immunological screening of phage displayed RPLs
Specific phage clones for the UN1 mAb were isolated from the library by two rounds of
affinity selection, as previously described (38, 39). To this end, the UN1 mAb (10 μg) was
linked to streptavidin-conjugated magnetic beads (Promega, Madison, WI, USA), which had
been coated with 10 μg of goat anti-mouse IgG (Fc-specific) biotin-conjugated Ab (Sigma-
Aldrich) in 200 μl of beads suspension. A total of 3×1010 transducing units (TU) of phages
from the library were added and incubated for 16 hours at 4°C. After extensive washing,
bound phages were eluted with 0.1 M HCl/glycine buffer pH 2.2, 1 mg/ml BSA, and
neutralized with 1 M Tris pH 9.1. Eluted phages were amplified by infection of K91BK
bacteria, and purified from plaques for a second round of affinity selection. Phage colonies
were transferred according to an ordered grid on a lawn of K91BK cells on LB agar plates
supplemented with 1mM IPTG. Nitrocellulose filters were layered onto these plates and
incubated overnight at 37°C. Filters were blocked for 2 hours with blocking buffer (1× PBS,
5% non-fat dry milk, 0.1% NP40, 0.01% NaN3) at room temperature and incubated O/N at
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4°C with the UN1 mAb (1 μg/ml) in blocking buffer. Then, filters were washed with
washing buffer (1× PBS, 0.1% NP40) and incubated with alkaline phosphatase-conjugated
anti-mouse IgG (Fc specific) secondary antibody (Sigma-Aldrich) at the dilution of 1:5000
for 4 hours at 4°C. After extensive washing, filters were incubated in developing solution (1-
Step NBT/BCIP, Pierce, Thermo Scientific, Rockford, IL, USA). Collected phage
supernatants from positive clones were further analysed by ELISA.
ELISA
For assaying phage reactivity to antibodies or sera, multiwell plates (Immunoplates
Maxisorp, Nunc, Milano, Italy) were coated with 10 μg/ml anti-fd bacteriophage Abs
(Sigma-Aldrich) in 50 mM NaHCO3, pH 9.6 overnight at 4°C. After blocking with Blocking
Buffer (BB) (1× PBS, 5% non-fat dry milk, 0.05% Tween 20, 0.05% NaN3) for 1 hour at
37°C, the BB was discarded, and a mixture of 50 μL of BB and 50 μL of phage supernatant
was added to each well. After incubation for 1 hour at 37°C, plates were washed six times
with Washing Buffer (WB) (1× PBS, 0.05% Tween 20, 0.05% NaN3). Then, UN1 mAb (5
μg/mL) or sera at the indicated dilution were resuspended in BB and added to the wells.
After an O/N incubation at 4°C, plates were washed 6× with WB, and a 1:5000 dilution in
BB of a goat anti-mouse IgG (Fc specific) alkaline phosphatase antibody (Sigma-Aldrich)
was added to wells. Alkaline phosphatase was revealed by incubation with p-nitrophenyl
phosphate (1 mg/ml) in 1× diethanolamine substrate buffer (Pierce Thermo Scientific).
Optical density (OD) at 450 nm (OD405) and 620 nm (OD620) were measured by an ELISA
reader (Tecan, Männedorf, Switzerland), and values were expressed as difference between
OD405 and OD620. Wild type phage was used as negative control (40).
For assaying peptide reactivity to antibodies or sera, multiwell plates were coated with the
indicated peptide (5 μg/mL) in 1× PBS pH 7.4. After blocking with BB, the UN1 mAb (5
μg/ml), or the indicated mice sera were diluted in blocking buffer and incubated O/N at 4°C.
The following steps were as described above. A scrambled peptide was used as a negative
control.
Surface Plasmon Resonance
Surface plasmon resonance (SPR) was performed using Biacore 3000 optical biosensor
equipped with research-grade CM5 sensor chips (Biacore GE Healthcare), as previously
described (41). Experimental details are provided in Supplementary Materials and Methods.
Competition assay of UN1 mAb binding
The UN1 mAb (0.37 μg/mL) was pre-incubated O/N at 4°C with CsCl-purified phages
(3×1012 up to 3×108 phage particles/ml), or with synthetic peptides (0.04 μg/mL up to 400
μg/mL). The mixture was added to HPB-ALL cells (5×105) and incubated for 30 min at
4°C. After washing, the cells were incubated for additional 30 min at 4°C with FITC-
conjugated rabbit anti-mouse immunoglobulins F(ab')2, and analyzed with BD
FACSCalibur cytometer. Results were analyzed by CellQuest software (BD Biosciences,
Erembodegem, Belgium) (42).
Mice immunization
Five-six week old female Balb/c mice (Harlan, Udine, Italy) were immunized by intra-
peritoneal injection of CsCl-purified 2/165 phage particles, or wild type phage at weeks 0, 3,
6, 9, 12, 15, 18. The animals were bled at day 0 and 7-10 days after the 2nd, 4th and 6th
boost. Phages were injected as PBS suspension in CFA (Freund's complete adjuvant) at
week 0 or IFA (Freund's incomplete adjuvant) at a concentration of 6x1012 phage particles/
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mL. Serum IgGs from mice immunized with 2/165 phage, or wild type phage, or not-
immunized were purified by MAbTrap kit (GE Healthcare).
In vivo toxicity
Serum levels of inflammatory interleukin-1-β (IL1-β) were measured by ELISA (e-
Biosciences), according to the manufacturer's instructions. The hepatotoxicity marker
glutathione (GSH) and lactate dehydrogenase (LDH) were assayed by a colorimetric assay
(Promega), according to the manufacturer's instructions.
Immunoaffinity purification of antibodies
Immunoglobulins were purified by incubating mice sera at 1:10 dilution in multi-well plates
coated with 5×1012/ml CsCl-purified phages. After extensive washing, the bound
immunoglobulins were eluted with 0.1 M glycine-HCl buffer pH 2.7, 10 μg/ml BSA
immediately neutralized with 2 M Tris-HCl pH 9.4, and concentrated using Microcon
Ultracel YM-30 (Millipore, Bedford, MA, USA).
Immunohistochemistry
Surgical specimens were derived from breast and gastric cancer tissues of the patients
hospitalized at the clinical surgery Federico II University of Naples. The informed consent
to research activity was expressed by patients at the time of surgery for excision of
neoplasia, analysed at the section of Pathological Anatomy (department of advanced
biomedical sciences Federico II University of Naples). Immunohistochemical analysis was
performed as previously described (6, 7). Experimental details are provided in
Supplementary Materials and Methods.
Statistical analysis
Statistical analysis of tumor growth (Wilcoxon rank sum test and Wei-Johnson test) and
survival (Long-Rank Mantel-Cox test) were performed with GraphPad Prism 5 program
(GraphPad Software Inc., San Diego, CA). For ADCC assay, statistical analysis was
performed using Prism software (GraphPad Software Inc.). Data were analysed using paired
two-tailed Student's t test. Differences were considered as statistically significant at the 95%
level (p < 0.05).
Ethics Statement
This study was carried out according to the recommendations of the Institutional animal care
guidelines, Italian D.L. n. 116 of 27 January 1992 and European Communities Council
Directive 2010/63EU.
Results
UN1 mAb inhibited the tumor growth of UN1-positive leukemic T-cells in nude mice
Based on the evidence that the UN1 mAb specifically bound to UN1/CD43-positive
neoplastic cells (6, 7), we addressed the question of whether it could interfere the tumor
growth in vivo. To this end, ten female six-weeks old NU/NU nude mice were tumor
engrafted by subcutaneous injection of UN1-positive HPB-ALL cells into the lateral flank.
Then, mice were randomly divided in two groups (5 animals/group) and treated with the
UN1 mAb or IgG1 control (400 μg/mouse) by injection in the tail vein at day 1 and 7 after
tumor engraftment. Tumor onset and volume were monitored from day 0 up to 31, when all
mice of the IgG1 control group died. Tumor onset was observed at day 17 in IgG1-treated
mice, while it was delayed up to day 24 in UN1 mAb-treated mice. A statistically significant
inhibition of tumor growth was observed in UN1 mAb-treated mice as compared to IgG1-
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treated controls from day 17 to 31 (p < 0.032 by the Wilcoxon rank sum test and p = 0.024
by Wei-Johnson test) (Figure 1A). Mice survival was also significantly affected by the UN1
mAb treatment. In fact, the animal group treated with UN1 mAb showed 40% survival rates
at day 50 as compared to the death of IgG1-treated control group (p = 0.0031 by log-rank
Mantel-Cox test) (Figure 1B). These data showed that mAb UN1 treatment had an anti-
tumour activity in the HPB-ALL tumor xenograft mice model.
UN1 mAb caused HPB-ALL cell lysis via antibody-dependent cell-mediated cytotoxicity
To understand the mechanism of UN1 mAb-inhibition of HPB-ALL tumor growth, we
analysed the direct effect of the UN1 mAb on cell growth by incubating the HPB-ALL cells
with the UN1 mAb (1 up to 25 μg/ml), or IgG1 negative control. The UN1 mAb did not
affect the proliferation rate, cell cycle, the number of viable and apoptotic cells as compared
to untreated or IgG-treated cells (Fig. S1 A-D). Further, we analysed whether the UN1 mAb
could act via complement-mediated cell lysis. Cytotoxicity was assessed by incubating
HPB-ALL cells with or without UN1 mAb, in presence or absence of the complement.
W6/32 mAb and IgG were included as positive and negative controls, respectively.
Differently from W6/32 mAb, the UN1 mAb did not affect cell lysis (Fig 1C).
The antibody-dependent cell-mediated cytotoxicity (ADCC) is triggered by the binding of
antibody-opsonised tumour cells to FcγRIIIA/CD16 of NK cells resulting in tumour cell
lysis. Thus, we reasoned that ADCC could be a mechanism of UN1 mAb-dependent tumor
inhibition. To evaluate whether the UN1 mAb induced CD16-mediated ADCC, HPB-ALL
cells were opsonized with the UN1 mAb, or OKT3 or W6/32 mAbs as positive controls.
Cultured primary NK cells from nine healthy donors were tested in a standard ADCC assay.
A significant antibody-mediated lysis of tumor cells (p = 0.0026) was observed in the UN1
mAb-opsonized samples as compared to not-opsonised controls, being the UN1-opsonized
targets were killed more efficiently in seven out of nine donors (Fig. 1D). Moreover, ADCC
induced by UN1 mAb was slightly lower as compared to W6/32 mAb (mean 21.9% vs
24.4%), or OKT3 mAb (mean 21.9% vs 32.3%) (Fig. 1D). The ability of UN1 mAb to
induce ADCC was also supported by the analysis of lytic units within the same donor, which
were calculated for the whole curve effector/target cells (E/T) ratio (Fig. 1E). For the UN1,
OKT3 and W6/32 mAbs the strenght of binding to HBP-ALL cells directly correlated with
their ADCC potency (Fig. S2A), which was likely due to the expression levels of cognate
antigens on cell surface.
Identification of the UN1 mimotope by phage displayed RPL
Based on the UN1 mAb inhibition of UN1-positive tumor cells, we reasoned that the
identification of the UN1/CD43 epitope recognized by the UN1 mAb could be useful for
developing novel immunogens for cancer immunotherapy. To this end, we used the UN1
mAb to screen an f88-4/Cys5 phage displayed peptide library by two rounds of affinity
selection. A phage enrichment was observed during the selection as the output/input phage
ratio increased from 1.1x10-6 after round I to 1.2x10-2 after round II. After an
immunoscreening step, 174 single phage clones were recovered and tested by ELISA for
specific binding to the UN1 mAb and, among them, 153 clones were found to react with the
UN1 mAb. OD values of positive phagotopes ranged between 4 - 40 folds higher than wild
type phage (Fig. 2A). Based on these results, 28 phage clones showing the strongest positive
signal were selected for DNA sequencing, which yielded 11 different peptide mimotopes
sequences (Table 1). MUSCLE-based alignment analysis (http://www.ebi.ac.uk/Tools/msa/
muscle/) showed a significant homology between the 11 peptides and the human protein
CD43 (Fig. 2B), which is the natural antigen recognized by UN1 mAb (4). Indeed, the
homology region of the 11 amino acidic sequences of mimotopes falls in the extra-cellular
domain of CD43 (amino acids 64 to 83), a region that undergoes highly O-linked
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glycosylation (4). Among the 11-selected clones, the phagotope 2/165 was chosen due to the
strongest reactivity against UN1 mAb in ELISA (Table 1).
Two peptides were synthesized corresponding to the insert of the 2/165 phagotope (W15
peptide: TPHTCKLLDECVPLW) and a longer synthetic peptide containing the W15
peptide sequence with additional amino acid residues flanking the insert of the phagotope
2/165 (G23 peptide: SFAATPHTCKLLDECVPLWPAEG). As negative control, a
scrambled peptide was synthesized (TCLAPDVPEPLSHCWAGETFKLA). By surface
plasmon resonance (SPR), we measured binding affinity of the peptides W15 and G23 to the
UN1 mAb. Sensorgrams showed that G23 and W15 peptides exhibited similar affinities for
the UN1 mAb (KD 155 nM and 142 nM, respectively) while the scrambled peptide failed to
give the SPR signal (Fig. 2C).
Phagotope 2/165 and UN1 peptide mimotopes competed the binding of UN1 mAb to tumor
cells
Next, we determined whether the phage clone 2/165 and the peptides W15 and G23 mimic
the structure of the UN1 epitope. To this end, we performed a competitive inhibition assay
for the binding of the UN1 mAb to the HPB-ALL cells in presence or absence of the
phagotope 2/165 or the peptide mimotopes. The binding of UN1 mAb to HPB-ALL cells
was significantly reduced in presence of phage 2/165 (Fig. 3A, B), G23 or W15 peptides
(Fig. 3C, D) in a dose-related manner. This effect was not observed in presence of wild type
phage or scrambled peptide (Fig. 3A-D). Conversely, the phage 2/165 and the peptides G23
and W15 did not compete the binding of W6/32 mAb, an anti-human HLA class I antigen
(Fig. S2B). As additional evidence of structural similarity to the UN1/CD43 epitope, the
phage 2/165 and G23 competed the binding of UN1 mAb to UN1-positive breast and gastric
cancer tissues, while the wild type phage and scrambled peptide did not (Fig. S3). These
results indicated that the phagotope 2/165 as well as the derived G23 and W15 peptides
mimicked the conformation of the UN1/CD43 epitope.
Mice immunization with phagotope 2/165 elicited antibodies against the UN1/CD43 natural
antigen
Filamentous phage can be used as immunogen as they elicit a strong antibody response in
different animal systems (43, 44). Thus, we analysed the immunogenicity of the phagotope
2/165 in mice. Balb/c mice (5 animals/group) were immunized with the phage 2/165, or wild
type phage, and the collected sera were analysed for reactivity against the wild type phage,
G23 or a scrambled peptide as control (Fig. 4). Both wild type phage- and 2/165 phagotope-
immunized mice appeared healthy and did not show any ill-effect. Moreover, both groups of
immunized mice showed levels of serum inflammatory cytokine IL1-β and hepatotoxicity
marker GSH and LDH in the range of normality (Table 2), indicating that phage
immunization was not toxic.
As expected, both groups of immunized mice developed a strong and comparable antibody
response against the wild type phage, while control serum from a non-immunized mouse
showed no reactivity (Fig. 4A, B, left panels). However, the phagotope 2/165-immunized
mice sera showed a specific immune response against the UN1 mimotope G23 peptide
(1:20,000 up to 1:100,000 antibody titer) (Fig. 4A, middle panel), while they were
unreactive against the scrambled peptide (Fig. 4A, right panel). As negative control, the pre-
immune and wild type-phage immunized mice sera did not show any detectable reactivity
against the G23 (Fig. 4B, middle panel), or scrambled peptide (Fig. 4B, right panel). As
further analysis of 2/165 phagotope-induced antibodies recognition of UN1 epitope,
immunoglobulins were affinity-purified from sera of 2/165 phagotope immunized mice or
pre-immune sera using the 2/165 phagotope or wild type phage as ligand. The
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immunoglobulins (Igs) eluted from 2/165 phagotope (2/165 Igs) reacted with the G23
peptide, whereas Igs eluted from wild type phage (wt Igs) did not (Fig. S4A). Further, by
flow cytometry we confirmed that the 2/165 Igs bound to the HPB-ALL cells (Fig. S4B). On
the basis of the reported reactivity of the UN1 mAb with tumor tissues (6, 7), we tested
whether the 2/165 IgGs detected UN1-positive human breast and gastric cancer by
immunohistochemistry. We found that 2/165 IgGs specifically reacted with breast and
gastric cancer tissues with a pattern similar to the one observed with the UN1 mAb (Fig. 5).
Conversely, no reactivity against the cancer tissues was observed using the wt IgGs or pre-
immune IgGs (Fig. 5). The binding specificity of the 2/165 IgGs to UN1-positive cancer
tissues was confirmed by competition assays. Indeed, the pre-incubation of 2/165 IgGs with
the 2/165 phagotope or the UN1 mimotope G23 peptide inhibited the binding of 2/165 IgGs
to UN1-positive tumor tissues, confirming the binding specificity of 2/165 IgGs to the UN1
epitope exposed on tumor cells (Fig. 6).
Discussion
CD43 is a transmembrane sialoglycoprotein that is mostly expressed in haematopoietic cells,
and tumor cells of non-haematopoietic origin. CD43 signalling activates cellular pathways
leading to activation of NF-κB and AP1 transcription factors that up-regulate the expression
of pro-survival and proliferation genes (45). Deregulation of CD43 signalling can promote
cancer phenotype (45). We previously reported that specific CD43 glycoforms were
recognized by the UN1 mAb and were highly expressed in lymphoblastoid T-cell lines and
several solid tumors (4, 6, 7). In particular, the expression of UN1-type CD43 in breast
cancer correlated with the grade of malignancy, suggesting that the specific CD43
glycoforms could promote an altered proliferation signalling and cause cancer progression
(6, 7). Based on this evidence, the UN1 mAb was considered a suitable tool for cancer
immunophenotyping.
The aim of this study was to evaluate the immunotherapeutic activity of the UN1 mAb based
on the ability of this monoclonal antibody to target specifically the cancer cells expressing
the UN1-type CD43 glycoforms. We observed that the passive transfer of the UN1 mAb
inhibited the growth of UN1-positive HPB-ALL lymphoblastoid T-cells upon xenograft in
mice, suggesting a possible use of this antibody for cancer immunotherapy. We excluded
that tumor growth inhibition was due to direct cytostatic or cytotoxic activity of the UN1
mAb since the proliferation rate, cell cycle, and viability of HPB-ALL cells were unaffected
by the UN1 mAb in cell culture. Conversely, the UN1 mAb induced the in vitro lysis of
HPB-ALL cells via antibody-dependent NK-mediated cytotoxicity. Based on these findings,
the UN1 mAb behaved similarly to the antibodies that are currently used in cancer therapy
against specifically or differentially expressed tumor antigens, such as anti-CD20
(rituximab), anti Her-2/neu (trastuzumab), and anti-EGFR (cetuximab) (46). It is worth
mentioning that such validated anti-cancer therapeutic mAbs exhibited multiple effector
mechanisms for their in vivo anti-tumour activity (46). Even though additional mechanisms
of UN1 mAb action require further investigation, such as receptor down-modulation, ligand
blockade or antibody-dependent cellular phagocytosis (ADCP), the in vitro analysis
performed in this study indicates that ADCC could be a major mechanism of in vivo anti-
tumor activity.
We also explored the possibility to generate a mimotope of the UN1/CD43 epitope to be
used as immunogen for eliciting highly specific Abs against the UN1-positive tumor tissues.
By screening an f88-4/Cys5 phage displayed peptide library with the UN1 mAb, we
identified and characterized eleven peptide binders of the UN1 mAb. Among the selected
phage clones, the peptide insert of phagotope 2/165 was a true UN1/CD43 epitope mimic
because it was specifically recognized by the UN1 mAb and inhibited the binding of the
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UN1 mAb to the UN1/CD43 natural antigen, meeting the previously established guidelines
for specificity and mimicry testing (47). Several studies have indicated that cysteine-
constrained phage displayed peptides are endowed with a stabilized conformation that
allows the isolation of cyclic peptides with a higher affinity toward a bait as compared to
non-constrained, linear peptides (48). Moreover, cysteine-constrained phage-derived
peptides have been shown to bind the cognate ligand outside of the phage coat protein (38),
either in a different protein back-bone (49), or when coupled to therapeutic agents (50). In
these settings, the 2/165 peptide could represent a flexible tool for the targeted therapy of
UN1-positive tumor cells.
Bioinformatics-based analysis identified a significant sequence homology between the
eleven UN1 peptide mimotopes and the amino acids 64 to 83 contained in the extra-cellular
domain of CD43 that undergoes heavy O-glycosylation. These findings agree with our
previous observation that the monosaccharide GalNAc-O-linked to the CD43 peptide core
was an essential component of the UN1 epitope (4), and suggests the hypothesis that the
UN1 peptide core overlaps the sequence from 64 to 83 amino acids of the CD43 extra-
cellular domain.
For vaccine purpose, glycosylated antigens are difficult to synthesize and purify in large
quantities, and usually induce a poor immune response with short-lived IgM-type antibodies.
Novel strategies of vaccine production are required to overcome these major limitations
(17). Phage mimotopes of cancer antigens (18, 21-23), revealed a promising activity as
immunogens by eliciting a strong cross-reactive antibody response against the selected
natural antigens. Here, we have demonstrated that the phagotope 2/165 mimicked the
cancer-associated UN1/CD43 epitope and induced in immunized mice specific antibodies
against the UN1/CD43 antigen. In fact, purified immunoglobulins from 2/165 phagotope-
immunized mice sera specifically reacted with several UN1-positive cancer tissues, as
confirmed by competition assays. Further, the UN1 mimotope-induced antibodies were IgG
isotype, a peculiar feature of a long-standing-immune response, indicating that the
mimotope-based immunization can overcome the poor immunogenicity of purified
glycosylated antigens.
Based on these results, the UN1/CD43 epitope may represent a suitable target for cancer
immunotherapy, and UN1 mimotopes, such as 2/165 phagotope and derivative G23 peptide
here described, are promising cancer vaccine candidates for UN1-positive tumors.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. UN1 mAb inhibited UN1-positive tumor growth via ADCC
(A) UN1 mAb treatment resulted in tumor growth inhibition in mice engrafted with HPB-
ALL lymphoblastoid T-cells. Tumour growth curves (mean tumour volume ± SEM) in
HPB-ALL xenograft mice models treated with control IgG (400 μg in PBS/mouse) or UN1
mAb (400 μg in PBS/mouse). Arrows indicate the time of antibodies administration. A
representative of 2 independent experiments with similar results is shown. (B) UN1 mAb
treatment resulted in improved survival of mice engrafted with HPB-ALL lymphoblastoid
T-cells. Kaplan-Meier survival curves of HPB-ALL xenografted mice treated with control
IgG1 or UN1 mAb are shown. (C) UN1 mAb did not mediate complement-dependent
cytotoxicity. HPB-ALL cells were pre-incubated with UN1 mAb (200 μg/ml), W6/32 mAb
(100 μg/ml), IgG (200 μg/ml), or without antibodies (w/o mAb), and then incubated in
presence or absence (w/o compl.) of complement for a standard complement-dependent
cytotoxicity assay. The W6/32 mAb was a positive control. The mean of dead cells ± SD of
each experimental point is shown. (D) UN1 mAb mediated antibody-dependent NK
cytotoxicity of HPB-ALL cells. Primary cultured human NK cells derived from different
donors (n=9) were allowed to bind to UN1-, W6/32-, OKT3- opsonized or not opsonized (no
mAb) HPB-ALL target cells and tested in ADCC assay. The mean percentage ± SD of
specific lysis at E:T ratio 6:1 is shown. The p-values of UN1-, W6/32-, or OKT3- specific
lysis versus no mAb-specific lysis were calculated by paired two-tailed Student's t test, and
are indicated by asterisks, as follows: (*) p=0.0026; (**) p=0.0008; (***) p=0.0001. (E)
Results expressed as lytic units/106 cells of the ADCC assay described in D. Each curve
represents a single donor.
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Fig. 2. Binding analysis of phagotopes and peptides to UN1 mAb
(A) ELISA binding analysis of 174 selected phages clones to UN1 mAb. Each phagotope
was tested in duplicate and the relative absorbance was calculated as the difference between
OD405nm and OD620nm. Relative OD indicates the ratio of the mean OD value of the tested
phagotope to the mean OD value of the wild type phage.
(B) MUSCLE-based alignment of peptide sequence of selected phagotopes with CD43
protein. The positions of amino acids in CD43 aligned sequence are indicated.
(C) Affinity measurement of G23 and W15 peptides binding to UN1 mAb by Surface
Plasmon Resonance (SPR). The sensorgrams show G23 peptide, W15 peptide and
scrambled peptide binding to UN1 mAb immobilized on CM5 sensor chip. The peptide
concentrations used were 0.1, 0.25, 0.5, 1.0 and 2.5 mM. The response expressed in
resonance units was recorded as a function of time. For G23 and W15 peptide, the
corresponding KD is indicated.
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Fig. 3. Phage clone 2/165 and the derivative peptides inhibited the binding of mAb UN1 to UN1-
positive cancer cells
(A) Phagotope 2/165 inhibited the UN1 mAb binding to UN1-positive HPB-ALL cells. The
mAb UN1 (0.37 μg/ml) was pre-incubated with the indicated doses of 2/165 phage (left
panel) or wild type phage (right panel), and then added to HPB-ALL cells (5x105). Cell-
bound UN1 mAb was revealed by flow cytometry. Histogram overlays of the UN1 mAb
fluorescence intensity are shown. (B) Percentage of HPB-ALL cells recognized by mAb
UN1 for the experiment described in A. (C) Synthetic peptides G23 and W15 inhibited the
UN1 mAb binding to UN1-positive HPB-ALL cells. The mAb UN1 (0.37 μg/ml) was pre-
incubated with the indicated doses of G23 (left panel), W15 (middle panel) or scrambled
(right panel) peptides, and then added to HPB-ALL cells (5x105). Cell-bound UN1 mAb
was revealed by flow cytometry. Histogram overlays of the UN1 mAb fluorescence intensity
are shown. (D) Percentage of HPB-ALL cells recognized by mAb UN1 for the experiment
described in B.
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Fig. 4. Reactivity of immunized mice sera
(A,B) Reactivity against wild type phage, G23- or scrambled-peptide of sera from 2/165
phagotope-immunized mice (samples 1, 2, 5 and 13) (panel A), or wild type phage-
immunized mice (samples 7, 8, 9, 10 and 11) (panel B), as evaluated by ELISA. Relative
OD was calculated as the difference between OD405nm and OD620nm. Sera dilutions are
indicated on abscissa.
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Fig. 5. The 2/165 phage-induced antibodies detected UN1-positive human breast and gastric
cancer tissues
Serial sections of surgical specimens derived from breast and gastric cancer tissues were
stained with UN1 mAb, 2/165 IgGs (IgGs purified from sera of 2/165 phagotope-immunized
mice), wt IgGs (IgGs purified from sera of wild type phage-immunized mice) or control
IgGs (IgGs purified from not-immunized mice), according to peroxidase-antiperoxidase
method. Original magnification ×200.
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Fig. 6. The 2/165 phagotope and G23 peptide inhibited the binding of 2/165 IgG to human breast
and gastric cancer tissues
Serial sections of surgical specimens derived from breast and gastric cancer tissues were
stained with 2/165 IgGs, pre-incubated overnight at 4°C with the indicated phage (2.5x1013
phage particles/mL) or peptide (500 μg/mL), according to peroxidase-antiperoxidase
method. Original magnification ×200.
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Table 1
Sequences of UN1 mAb-selected mimotopes
Amino acid sequences of selected mimotopes. Frequency indicates the recurrence of the same sequence in
different phage clones. OD405-OD620 refers to the ELISA results of phage reactivity to UN1 mAb.
Phage Number Peptide Sequence Frequency OD405-OD620
1.5 SRPHCYPMDDCHPLW 4 1.137
1.201 LMSTCTWLDECFRPQ 6 1.025
2.16 PTPPCHRGDECQPLW 5 0.703
2.165 TPHTCKLLDECVPLW 3 2.925
2.171 TPTVCTWLDECPPWS 1 1.052
2.207 WSGMCESQWCKDFA 4 1.039
3.109 HTPWCSIADPCLWEL 1 1.597
3.158 YHEPCLWATACPTTP 1 0.464
3.206 MQDMCNDDSCPLWS 1 0.481
2.110 CTHPCEPPPLWPIAP 1 2.082
2.8 PGPQCPYPAELWCTQ 1 0.336
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Table 2
In vivo toxicity of phage immunization
Balb/c mice (5 animals/group) were immunized with the phage 2/165, or wild type phage, or left untreated,
and the collected sera at days 7-10 from the 6th boost were analysed for the indicated markers of systemic
toxicity. Values represent the mean ± SEM of sample measurements.
Group IL-1β (pg/mL) GSH (μM) LDH (IU/L)
Untreated 58.0 ± 0.2 10.4 ± 1.2 65.4 ± 12.3
Wt phage 59.7 ± 0.3 9.8 ± 0.8 60.0 ± 11.5
2/165 phage 58.2 ± 0.3 10.1 ± 0.9 52.9 ± 15.4
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